FDA approves expanded labeling for dorsal root ganglion stimulation therapy

The FDA has approved expanded MRI labeling for Abbott’s dorsal root ganglion stimulation therapy, which allows those with complex regional pain syndrome to receive full-body MRI scans while implanted with the device.
According to a company press release, the Proclaim DRG neurostimulation system is the only FDA-approved DRG technology that offers targeted relief for individuals with complex regional pain syndrome (CRPS) types I and II in the lower limbs by stimulating the dorsal root ganglia, clusters of nerve cells found along the spine.
CRPS is a rare and painful condition affecting

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart